Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York
Median Technologies and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at this landmark meeting of the international lung cancer screening community
I-ELCAP has played a pioneering role in advancing the scientific evidence and international adoption of low-dose CT lung cancer screening
The conference will bring together many of the world's leading experts in lung cancer screening, including I-ELCAP pioneers
Following FDA clearance and CE marking, Median Technologies and eyonis Inc. are advancing the commercial deployment of eyonis® LCS in the United States, its primary market, and Europe
SOPHIA ANTIPOLIS, France, October 20, 2026--Regulatory News:
Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that the Company and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at the 50th International Conference on Screening for Lung Cancer organized by I-ELCAP (The International Early Lung Cancer Action Program) and taking place October 22-24, 2026, at the Icahn School of Medicine at Mount Sinai in New York City.
The 50th I-ELCAP conference marks an important milestone for this pioneering lung cancer screening initiative, bringing together many of the world's leading experts in the field. For decades, I-ELCAP has helped build the scientific and clinical foundations for low-dose CT (LDCT) screening and its implementation worldwide. As organized screening programs continue to expand, I-ELCAP's experience and international network play a key role in supporting broader adoption.
"I-ELCAP brings together a unique international community of experts and clinicians committed to advancing lung cancer screening and improving early detection," said Fredrik Brag, CEO and Founder of Median Technologies. "For Median, presenting at I-ELCAP's 50th conference is an opportunity to contribute to this global momentum and share our vision of how AI can support the next phase of lung cancer screening."
"Turning broader lung cancer screening into clinical reality requires solutions that fit seamlessly into radiologists' daily workflows and help them manage increasing screening volumes," added Oran Muduroglu, President of eyonis Inc. "This is where eyonis® LCS can make a very concrete contribution, providing AI-powered detection and diagnostic support within the lung cancer screening workflow, with the objective of helping health professionals deliver screening efficiently and consistently at scale."